Article Figures & Data
Figures
- FIGURE 1.
Between December 2006 and November 2009, there were 1,075 registered patients, for which 467 were complete datasets, with documentation for at least 12 mo.
- FIGURE 2.
Time to progression according to indication (first line, consolidation after first-line and primary therapy vs. recurrence and therapy refractory, other) for patients with FL (log-rank test, P = 0.052) (A) and with other lymphoma subtypes (log-rank test, P = 0.18) (B).
- FIGURE 3.
Use of radioimmunotherapy by line of treatment.
- FIGURE 4.
OS (A) and PFS (B) according to lymphoma subtype.
Tables
Characteristic n No. of patients 467 Sex Men 250 Women 217 Age (y) Median 59 Range 17–88 No. of patients older than 60 y 210 (45) Lymphoma subtype FL I–III a 271 (58) Diffuse large B-cell lymphoma 94 (20) Mantle cell lymphoma 65 (14) B-chronic lymphatic leukemia 24 (5.1) Marginal zone lymphoma 13 (2.8) Stage I 24 (5.2) II 63 (13.5) III 104 (22.3) IV 268 (57.4) E 4 (0.9) Not determined 4 (0.9) Previous therapies Chemotherapy 445 1–3 342 (77) 4–6 89 (20) >7 14 (3) Radioimmunotherapy 22 (4.7) Autologous stem cell transplantation 1 63 (13.4) 2 3 (0.6) Radiotherapy 88 1 67 (76) 2 16 (18) ≥3 5 (6) Bone marrow infiltration before radioimmunotherapy No. of patients 467 Infiltration 72 (15) <20% 59 (13) >20% 13 (3) Data in parentheses are percentages.
Follicular lymphoma, line (n = 236) Other lymphoma subtypes, line (n = 172) Indication All First Second Third through eighth All First Second Third through eighth Consolidation 107 (45) 62 21 24 119 (69) 79 21 19 Conditioning 3 (1.3) 0 2 1 5 (2.9) 2 1 2 Primary therapy 3 (1.3) 3 0 0 5 (2.9) 5 0 0 Recurrence 89 (37.7) 0 30 59 23 (13) 0 7 16 Therapy refractory 28 (11.8) 1 3 24 6 (3.4) 0 1 5 Other 6 (2.5) 0 3 3 14 (8) 6 4 4 Data in parentheses are percentages.
FL Other lymphoma Response All First line* Relapse† No line available‡ First line* Relapse† No line available‡ CR 336 (75) 57 (87.7) 101 (58.4) 32 (91) 71 (84.5) 58 (66) 17 (77) Partial remission 70 (16) 5 (7.7) 36 (21) 1 (2.9) 11 (13) 15 (17) 2 (9) Stable disease 17 (4) 2 (3) 10 (5.8) 1 (2.9) 0 (0) 2 (2.3) 2 (9) Progressive disease 20 (4) 0 (0) 12 (7) 1 (2.9) 0 (0) 6 (6.8) 1 (4) ND 5 (1) 1 (1.5) 14 (8.1) 0 (0) 2 (2.3) 7 (8) 10 (3) * Consolidation first line or primary therapy.
† Recurrence or therapy-refractory.
‡ Line of therapy was not documented.
ND = not done.
Data in parentheses are percentages.
FL Other lymphoma Parameter n Median nadir n Median nadir Hemoglobin 243 10.8 g/dL 173 9.7 g/dL Leukocytes 179 2.0 μL 129 2.2 μL Platelets 245 194 μL 174 13.000 μL
